Biogen inks $37.5M licensing deal with MondoBiotech

Biogen Idec is paying $7.5 million up front and up to $30 million in milestones for the right to develop a new therapy for pulmonary arterial hyperntension from MondoBiotech. Biogen is looking to gain marketing rights for Aviptadil in the U.S. and Europe. Biogen also agreed to make an equity investment of $5 million in MondoBiotech. Aviptadil is a synthetically produced human peptide that met its primary endpoint in a Phase II trial.

- read the AP report on the deal

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.